14,378 Shares in Altimmune, Inc. (NASDAQ:ALT) Bought by XTX Topco Ltd

XTX Topco Ltd purchased a new stake in shares of Altimmune, Inc. (NASDAQ:ALT) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 14,378 shares of the company’s stock, valued at approximately $96,000.

A number of other large investors have also added to or reduced their stakes in ALT. Farallon Capital Management LLC boosted its holdings in shares of Altimmune by 1,282.4% during the first quarter. Farallon Capital Management LLC now owns 470,000 shares of the company’s stock worth $4,785,000 after purchasing an additional 436,000 shares during the period. Lighthouse Investment Partners LLC bought a new position in Altimmune during the 4th quarter valued at approximately $4,493,000. Knoll Capital Management LLC lifted its position in shares of Altimmune by 183.6% in the 1st quarter. Knoll Capital Management LLC now owns 567,219 shares of the company’s stock worth $5,774,000 after purchasing an additional 367,219 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Altimmune by 142.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock valued at $3,791,000 after purchasing an additional 335,444 shares in the last quarter. Finally, Gerber LLC purchased a new position in shares of Altimmune during the fourth quarter valued at about $2,878,000. Institutional investors own 78.05% of the company’s stock.

Wall Street Analyst Weigh In

ALT has been the subject of several research analyst reports. Piper Sandler restated an “overweight” rating and issued a $25.00 price objective on shares of Altimmune in a report on Friday, June 21st. Evercore ISI upgraded Altimmune to a “strong-buy” rating in a research note on Friday, August 9th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research note on Thursday, August 22nd. Finally, B. Riley reissued a “buy” rating and set a $20.00 price objective on shares of Altimmune in a research report on Monday, August 12th. Two research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Altimmune presently has an average rating of “Moderate Buy” and a consensus price target of $18.80.

Insiders Place Their Bets

In related news, Director David Drutz sold 16,011 shares of the company’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $6.90, for a total transaction of $110,475.90. Following the completion of the sale, the director now owns 41,958 shares in the company, valued at $289,510.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.10% of the stock is currently owned by insiders.

Altimmune Price Performance

Altimmune stock opened at $6.29 on Wednesday. Altimmune, Inc. has a one year low of $2.09 and a one year high of $14.84. The business’s fifty day moving average is $6.67 and its 200 day moving average is $7.20. The stock has a market capitalization of $445.97 million, a PE ratio of -3.96 and a beta of 0.08.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). Altimmune had a negative net margin of 24,778.97% and a negative return on equity of 53.09%. The company had revenue of $0.01 million for the quarter. During the same quarter in the previous year, the firm posted ($0.32) earnings per share. As a group, sell-side analysts expect that Altimmune, Inc. will post -0.54 EPS for the current fiscal year.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.